Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic products. The Company is focused on providing physicians with information that guide the healthcare management of their patients to prevent disease, delay the onset of disease, or catch the disease at an earlier stage when it is treatable. As of June 30, 2009, the Company launched seven commercial molecular diagnostic products, including four predictive medicine and three personalized medicine products. It markets the products through its 300-person sales force in the United States. On June 30, 2009, the Company spun-off its research and drug development businesses for the treatment of cancers and other diseases into its wholly owned subsidiary, Myriad Pharmaceuticals, Inc. (MPI).